Addressing challenges in the clinical applications associated with CRISPR/Cas9 technology and ethical questions to prevent its misuse.
10.1007/s13238-017-0477-4
- Author:
Xiang Jin KANG
1
;
Chiong Isabella Noelle CAPARAS
2
;
Boon Seng SOH
3
;
Yong FAN
4
Author Information
1. Key Laboratory for Major Obstetric Diseases of Guangdong Province, Key Laboratory of Reproduction and Genetics of Guangdong Higher Education Institutes, Center for Reproductive Medicine, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510150, China.
2. Disease Modeling and Therapeutics Laboratory, A*STAR Institute of Molecular and Cell Biology, 61 Biopolis Drive Proteos, Singapore, 138673, Singapore.
3. Key Laboratory for Major Obstetric Diseases of Guangdong Province, Key Laboratory of Reproduction and Genetics of Guangdong Higher Education Institutes, Center for Reproductive Medicine, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510150, China. bssoh@imcb.a-star.edu.sg.
4. Key Laboratory for Major Obstetric Diseases of Guangdong Province, Key Laboratory of Reproduction and Genetics of Guangdong Higher Education Institutes, Center for Reproductive Medicine, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510150, China. yongfan011@gzhmu.edu.cn.
- Publication Type:Journal Article
- MeSH:
Animals;
CRISPR-Cas Systems;
Cystic Fibrosis;
genetics;
therapy;
Gene Editing;
ethics;
Genetic Therapy;
ethics;
methods;
Humans;
Mice;
Neoplasms;
genetics;
therapy
- From:
Protein & Cell
2017;8(11):791-795
- CountryChina
- Language:English
